ADAPY — Adaptimmune Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.60m
- $10.22m
- $178.03m
Adaptimmune Therapeutics PLC expected to post a loss of 10 cents a share - Earnings Preview
Enters Settlement Agreement With MD Anderson - SEC Filing
Adaptimmune Therapeutics PLC reports results for the quarter ended March 31 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 12 cents a share - Earnings Preview
Enters Amendment To Loan And Security Agreement - SEC Filing
Adaptimmune Therapeutics PLC expected to post a loss of 13 cents a share - Earnings Preview
Adaptimmune Therapeutics PLC expected to post a loss of 15 cents a share - Earnings Preview
Adaptimmune Therapeutics PLC expected to post a loss of 15 cents a share - Earnings Preview
Adaptimmune Therapeutics PLC expected to post a loss of 15 cents a share - Earnings Preview
Adaptimmune Therapeutics PLC expected to post a loss of 15 cents a share - Earnings Preview
Gavin Wood To Step Down As Chief Financial Officer
Adaptimmune Therapeutics PLC reports results for the quarter - Earnings Summary
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Adaptimmune up as cancer therapy meets main goal in mid-stage study
Brief: Adaptimmune Therapeutics PLC Lete-Cel Achieves Primary Endpoint In Pivotal Trial
Adaptimmune Therapeutics PLC expected to post a loss of 13 cents a share - Earnings Preview
Brief: Adaptimmune Therapeutics gets Nasdaq notice for non-compliance with minimum bid price
Brief: Adaptimmune Therapeutics Entered Mutual Release And Resolution Agreement With Genentech Inc & F. Hoffmann-La Roche Ltd